8-K: BridgeBio Pharma Secures $300 Million Through Strategic Royalty Sale of Acoramidis in Europe

BridgeBio Pharma, Inc. and its subsidiary Eidos Therapeutics, Inc. have entered into an agreement to sell certain European royalty rights for acoramidis for $300 million in cash.

Summary

• BridgeBio Pharma, Inc. (the Company) and its subsidiary Eidos Therapeutics, Inc. (Eidos) sold certain rights to receive royalty payments (Purchased Royalty Payment) on net sales of products containing acoramidis (Licensed Products) in the European Union and European Patent Organization member states (Licensed Territory).
• The sale was made to Acoramidis Royalty SPV, LP and LSI Financing Fund, LP (the Purchasers).
• Eidos received $300 million in cash (Purchase Price) from the Purchasers, which was funded in full on June 27, 2025 (the Closing Date).
• The Purchasers' rights to the Purchased Royalty Payment are subject to an annual cap equal to 60% of all royalty payments paid by Bayer Consumer Care AG (Bayer) to Eidos and its affiliates on the first $500,000,000 of annual net sales of Licensed Products in the Licensed Territory.
• Additionally, the Purchasers' rights are subject to an initial hard cap equal to 145% of the Purchase Price, meaning a maximum total payment of $435 million ($300 million * 1.45).
• The royalty streams originate from an exclusive license agreement with Bayer Consumer Care AG (dated March 1, 2024) and an amended and restated license agreement with BridgeBio International GmbH (effective June 30, 2023).
• The Company and Eidos granted the Purchaser Representative a security interest in specific assets related to the Purchased Royalty Payment.
• Upon a change of control of the Company, the successor entity has an option to either assume the obligations or pay the Purchasers an Adjusted Amount.

Sentiment

Score: 7

Explanation: The transaction provides a significant cash infusion of $300 million, which is a positive for liquidity and funding future operations. While it involves monetizing future royalty streams, the terms include caps that limit the amount of future royalties given up, suggesting a balanced approach to non-dilutive financing. This is a strategic move to strengthen the balance sheet without equity dilution.

Positives

• Secured $300 million in immediate cash proceeds, significantly strengthening the company's liquidity and balance sheet.
• Monetized future royalty streams from acoramidis, providing non-dilutive capital without issuing new equity or incurring traditional debt.
• The transaction includes an initial hard cap of 145% of the Purchase Price ($435 million), limiting the total amount of future royalties given up to the Purchasers.

Negatives

• Forfeited a portion of future royalty payments from acoramidis sales in the European Union and European Patent Organization member states, reducing potential long-term revenue from this asset.
• The annual cap of 60% on the first $500 million of annual net sales means a significant portion of early-stage royalties from Bayer will be diverted to the Purchasers.

Risks

• The company's future revenue from acoramidis in the Licensed Territory will be reduced by the sold royalty interest, potentially impacting long-term cash flow from this asset.
• A security interest in specific assets related to the Purchased Royalty Payment has been granted, which could have implications in certain default scenarios.
• Upon a change of control, the successor entity has an option to either assume obligations or pay an 'Adjusted Amount,' which introduces a potential financial obligation or strategic decision point.

Future Outlook

The document does not provide explicit forward-looking statements or guidance beyond the terms of the royalty agreement itself. The transaction provides immediate capital, which could support future development or operations.

Industry Context

This transaction is a common strategy in the biotechnology and pharmaceutical industries for companies to monetize future revenue streams from approved or late-stage assets, especially for non-dilutive financing. It allows companies to raise capital without issuing new equity or incurring traditional debt, which can be particularly attractive for companies with significant R&D expenses or those looking to fund pipeline expansion.

Related Party Transactions

• The Purchased Royalty Payment is derived in part from an amended and restated license agreement, effective June 30, 2023, between Eidos Therapeutics, Inc. and BridgeBio International GmbH, which is one of the Company's other subsidiaries.

Stakeholder Impact

• Shareholders: The $300 million cash infusion strengthens the company's financial position without equity dilution, potentially supporting future growth initiatives and reducing immediate financing risks. However, it reduces future royalty income from acoramidis in the Licensed Territory.
• Creditors: Improved liquidity from the cash proceeds could enhance the company's ability to meet its financial obligations.
• Management: Provides capital flexibility for strategic decisions, including R&D investments and pipeline advancement.

Next Steps

• The complete text of the Purchase Agreement will be filed as an exhibit to a subsequent periodic report of the Company.

Key Dates

Recommendation

Keywords

BridgeBio Pharma, Eidos Therapeutics, Royalty Sale, Acoramidis, Biotechnology, Pharmaceuticals, Non-dilutive Financing, Drug Development, Rare Disease, SEC Filing, 8-K, Bayer License